World Lung 2025 – Ideaya challenges Zai Lab
Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.
Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.
Ocular toxicities could be the reason.
The group cans ZW171 after “on-target, off-tumour toxicity”.
China's Harmoni-A trial hits on overall survival, but hopes for a global phase 3 seem optimistic.
Posters and mini-orals include another VEGF bispecific.
Inclacumab fails, and osivelotor is on hold.